Schizophrenia Bulletin Index—1994–95

Author Index

A

Abel, K.; *see* Castle, D.J.

Albers, M.; *see* Martin, P.

Albus, K.E.; *see* Gordon, C.T.

Ament, A.J.H.A.; *see* Evers, S.M.A.A.

Amin, F.; Davidson, M.; Kahn, R.S.; Schmeidler, J.; Stern, R.; Knott, P.J.; and Apter, S. Assessment of the central dopaminergic index of plasma HVA in schizophrenia, 21(1):53–66, 1995.

Andrews, L.K.; *see* Werry, J.S.

Anonymous. First person account: Life with a mentally ill spouse, 20(1):227–229, 1994; First person account: Schizophrenia with childhood onset, 20(4):587–590, 1994.

Apter, S.; *see* Amin, F.

Asamen, J.; *see* Asarnow, R.F.

Asarnow, J.R.; *see* Asarnow, R.F.

Asarnow, J.R.; Tompson, M.C.; and Goldstein, M.J. Childhood-onset schizophrenia: A followup study, 20(4):599–617, 1994.

Asarnow, R.F.; Asamen, J.; Granholm, E.; Sherman, T.; Watkins, J.M.; and Williams, M.E. Cognitive/neuropsychological studies of children with a schizophrenic disorder, 20(4):647–669, 1994.

Asarnow, R.F., and Asarnow, J.R. Childhood-onset schizophrenia: Editors' introduction, 20(4):591–597, 1994; *see also* Benedict, R.H.B.; Strandburg, R.J.

B

Baltaxe, C.A.M., and Simmons, J.Q. III. Speech and language disorders in children and adolescents with schizophrenia, 21(4):677–692, 1995.

Bar-El, Y.; *see* Lerner, V.

Barr, C.L.; Kennedy, J.L.; Pakstis, A.J.; Castiglione, C.M.; Kidd, J.R.; Wetterberg, L.; and Kidd, K.K. Linkage study of a susceptibility locus for schizophrenia in the pseudoautosomal region, 20(2):277–286, 1994.

Barry, K.L.; Fleming, M.F.; Greenley, J.; Widlak, P.; Kropp, S.; and McKee, D. Assessment of alcohol and other drug disorders in the seriously mentally ill, 21(2):313–321, 1995.

Battaglia, M.; Bernardeschi, L.; Franchini, L.; Bellodi, L.; and Smeraldi, E. A family study of schizotypal disorder, 21(1):33–45, 1995.

Belcher, J.R.; *see* Thompson, J.W.

Bellodi, L.; *see* Battaglia, M.

Benedict, R.H.B.; Harris, A.E.; Markow, T.; McCormick, J.A.; Nuechterlein, K.H.; and Asarnow, R.F. Effects of attention training on information processing in schizophrenia, 20(3):537–546, 1994.

Beratis, S.; Gabriel, J.; and Hoidas, S. Age at onset in subtypes of schizophrenic disorders, 20(2):287–296, 1994.

Bernardeschi, L.; *see* Battaglia, M.

Bigelow, L.B.; *see* Torrey, E.F.

Blanchard, J.J.; Kring, A.M.; and Neale, J.M. Flat affect in schizophrenia: A test of neuropsychological models, 20(2):311–325, 1994.

Boccio-Smith, A.; *see* DeLisi, L.E.

Boumans, C.E.; de Mooij, K.J.; Koch, P.A.M.; van't Hof, M.A.; and Zitman, F.G. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia?, 20(2):339–344, 1994.

Bowler, A.E.; *see* Torrey, E.F.

Bracha, H.S.; *see* Davis, J.O.; Torrey, E.F.

Braun, C.M.J.; *see* Lapierre, D.

Brown, J.S., Jr. Geographic correlation of schizophrenia to ticks and tick-borne encephalitis, 20(4):755–775, 1994; Role of selenium and other trace elements

in the geography of schizophrenia, 20(2):387–398, 1994.
Brown, W.S.; *see* Strandburg, R.J.
Buchanan, R.W. Clozapine: Efficacy and safety, 21(4):579–591, 1995; *see also* Bustillo, J.
Bustillo, J.; Buchanan, R.W.; and Carpenter, W.T., Jr. Prodromal symptoms vs. early warning signs and clinical action in schizophrenia, 21(4):553–559, 1995.

C

Campbell, M.; *see* Spencer, E.K.
Cannon, T.D., and Marco, E. Structural brain abnormalities as indicators of vulnerability to schizophrenia, 20(1):89–102, 1994.
Caplan, R. Communication deficits in childhood schizophrenia spectrum disorders, 20(4):671–683, 1994.
Carpenter, W.T., Jr.; *see* Bustillo, J.; Lehman, A.F.
Carter, M.; *see* Hogarty, G.E.
Castiglione, C.M.; *see* Barr, C.L.
Castle, D.J.; Abel, K.; Takei, N.; and Murray, R.M. Gender differences in schizophrenia: Hormonal effect or subtypes?, 21(1):1–12, 1995.
Christenson, C.; *see* Green, M.F.
Claridge, G. Single indicator of risk for schizophrenia: Probable fact or likely myth?, 20(1):151–168, 1994.
Cohen, J.D., and Servan-Schreiber, D. Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20(3):417–421, 1994.
Constantineau, C.; *see* Lapierre, D.
Cooley, S.; *see* Hogarty, G.E.
Cornblatt, B.A., and Keilp, J.G. Impaired attention, genetics, and the pathophysiology of schizophrenia, 20(1):31–46, 1994.
Corrigan, P.W., and Toomey, R. Interpersonal problem solving and information processing in schizophrenia, 21(3):395–403, 1995.
Cott, J.; *see* Shore, D.
Coursey, R.D.; Keller, A.B.; Farrell, E.W. Individual psychotherapy and persons with serious mental illness: The clients' perspective, 21(2):283–301, 1995.
Crow, T.J.; *see* DeLisi, L.E.
Csernansky, J.G., and Newcomer, J.W. Are there neurochemical indicators of risk for schizophrenia?, 20(1):75–88, 1994.
Cuesta, M.J., and Peralta, V. Lack of insight in schizophrenia, 20(2):359–366, 1994; Psychopathological dimensions in schizophrenia, 21(3):473–482, 1995.

D

Daily, T.; *see* Penn, D.L.
Dassori, A.M.; Miller, A.L.; and Saldana, D. Schizophrenia among Hispanics: Epidemiology, phenomenology, course, and outcome, 21(2):303–312, 1995.
David, A.S. Dysmodularity: A neurocognitive model for schizophrenia, 20(2):249–255, 1994.
Davidson, M.; *see* Amin, F.
Davidson, M., and Powchik, P. Commentary to "Late-onset schizophrenia and late paraphrenia," 21(3):355–356, 1995.
Davis, D.; *see* Walker, E.F.
Davis, J.O., and Phelps, J.A. Twins with schizophrenia: Genes or germs?, 21(1):13–18, 1995.
Davis, J.O.; Phelps, J.A.; and Bracha, H.S. Prenatal development of monozygotic twins and concordance for schizophrenia, 21(3):357–366, 1995.
DeForge, B.R.; *see* Thompson, J.W.
DeGirolamo, J.; *see* Mueser, K.T.
DeLisi, L.E.; Friedrich, U.; Wahlstrom, J.; Boccio-Smith, A.; Forsman, A.; Eklund, K.; and Crow, T.J. Schizophrenia and sex chromosome anomalies, 20(3):495–505, 1994.
DeMann, J.A. First person account: The evolution of a person with schizophrenia, 20(3):579–582, 1994.
de Mooij, K.J.; *see* Boumans, C.E.
DiBarry, A.L.; *see* Hogarty, G.E.
Dixon, L.B.; *see* Lehman, A.F.; Scott, J.E.
Dixon, L.B., and Lehman, A.F. Family interventions for schizophrenia, 21(4):631–643, 1995.
Dixon, L.B.; Lehman, A.F.; and Levine, J. Conventional antipsychotic medications for schizophrenia, 21(4):567–577, 1995.
Docherty, N.M. Expressed emotion and language disturbances in parents of stable schizophrenia patients, 21(3):411–418, 1995.
Dose, M.; *see* Wiedemann, G.
Dworkin, R.H. Pain insensitivity in schizophrenia: A neglected phenomenon and some implications, 20(2):235–248, 1994.

E

Eklund, K.; *see* DeLisi, L.E.
Erlenmeyer-Kimling, L.; *see* Moldin, S.O.
Evers, S.M.A.A., and Ament, A.J.H.A. Costs of schizophrenia in The Netherlands, 21(1):141–153, 1995.

F

Faber, N.; *see* Kugelmass, S.
Faraone, S.V.; *see* Kremen, W.S.
Farrell, E.W.; *see* Coursey, R.D.
Feinstein, E.; *see* Wiedemann, G.
Ferstl, R.; Hanewinkel, R.; and Krag, P. Is the modality-shift effect specific for schizophrenia patients?, 20(2):367–373, 1994.
Fleishhacker, W.W.; *see* Meise, U.
Fleming, M.F.; *see* Barry, K.L.
Flesher, S.; *see* Hogarty, G.E.
Fleshner, C.L. First person account: Insight from a schizophrenia patient with depression,

21(4):703–707, 1995.
Forsman, A.; *see* DeLisi, L.E.
Förstl, H.; *see* Riecher-Rössler, A.
Fotyanov, M.; *see* Lerner, V.
Frances, A.; *see* Weiden, P.
Franchini, L.; *see* Battaglia, M.
Frazier, J.A.; *see* Gordon, C.T.
Frenkel, E.; *see* Ingraham, L.J.; Kugelmass, S.; Mirsky, A.F.
Frenkel, E.; Kugelmass, S.; Nathan, M.; and Ingraham, L.J. Locus of control and mental health in adolescence and adulthood, 21(2):219–226, 1995.
Friedman, D., and Squires-Wheeler, E. Event-related potentials (ERPs) as indicators of risk for schizophrenia, 20(1):63–74, 1994.
Friedrich, U.; *see* DeLisi, L.E.
Frisman, L.; *see* Rosenheck, R.
Fuchs, A.M. Clozapine: Benefits and risks (Letter to the Editor), 20(1):23, 1994.

G

Gabriel, J.; *see* Beratis, S.
Gallo, K.M. First person account: Self-stigmatization, 20(2):407–410, 1994.
Garbin, C.P.; *see* Penn, D.L.
Giedd, J.; *see* Gordon, C.T.
Gladis, M.M.; Levinson, D.F.; and Mowry, B.J. Delusions in schizophrenia spectrum disorders: Diagnostic issues, 20(4):747–754, 1994.
Goldman, D.; *see* Weiden, P.
Goldman, H.H.; *see* Lehman, A.F.
Goldstein, M.J.; *see* Asarnow, J.R.
Goodman, A.B. Medical conditions in Ashkenazi schizophrenic pedigrees, 20(3):507–517, 1994.
Gordon, C.T.; Frazier, J.A.; McKenna, K.; Giedd, J.; Zametkin, A.; Zahn, T.; Hommer, D.; Hong, W.; Kaysen, D.; Albus, K.E.; and Rapoport, J.L. Childhood-onset schizophrenia: An NIMH study in progress, 20(4):697–712, 1994.
Gottesman, I.I.; *see* Torrey, E.F.
Granholm, E.; *see* Asarnow, R.F.
Green, M.F.; Satz, P.; and Christenson, C. Minor physical anomalies in schizophrenia patients, bipolar patients, and their siblings, 20(3):433–440, 1994.
Greenley, J.; *see* Barry, K.L.
Greenwald, D.; *see* Hogarty, G.E.
Grove, W.M., and Iacono, W.G. Comment on Levy et al. "Eye tracking dysfunction and schizophrenia," 20(4):781–786, 1994.
Gruyters, T.; *see* Priebe, S.
Guthrie, D.; *see* Strandburg, R.J.
Guynan, K.; *see* Penn, D.L.

H

Häfner, H.; *see* Riecher-Rössler, A.
Hahlweg, K.; *see* Wiedemann, G.
Ham, M.; *see* Werry, J.S.
Hanewinkel, R.; *see* Ferstl, R.
Hank, G.; *see* Wiedemann, G.
Harris, A.E.; *see* Benedict, R.H.B.
Harrow, M.; *see* Jobe, T.H.
Harrow, M.; MacDonald, A.W. III; Sands, J.R.; and Silverstein, M.L. Vulnerability to delusions over time in schizophrenia and affective disorders, 21(1):95–109, 1995.
Harrow, M.; Yonan, C.A.; Sands, J.R.; and Marengo, J. Depression in schizophrenia: Are neuroleptics, akinesia, or anhedonia involved?, 20(2):327–338, 1994.
Harvey, E.J.; *see* Winefield, H.R.
Harvey, P.D.; *see* Serper, M.R.
Henderson, M.J.; *see* Thompson, J.W.
Herrig, E. First person account: A personal experience, 21(2):339–342, 1995.
Herz, M.I., and Lamberti, J.S. Prodromal symptoms and relapse prevention in schizophrenia, 21(4):541–551, 1995.
Heun, R.; *see* Maier, W.
Higgins, E.S.; *see* Torrey, E.F.
Higgins, P.B.; *see* Leadbetter, R.A.
Hodgins, S.; *see* Lapierre, D.
Hoffman, R.E., and McGlashan, T.H. Corticocortical connectivity, autonomous networks, and schizophrenia, 20(2):257–261, 1994.
Hogarty, G.E.; Kornblith, S.J.; Greenwald, D.; DiBarry, A.L.; Cooley, S.; Flesher, S.; Reiss, D.; Carter, M.; and Ulrich, R. Personal therapy: A disorder-relevant psychotherapy for schizophrenia, 21(3):379–393, 1995.
Hoidas, S.; *see* Beratis, S.
Holzman, P.S.; *see* Levy, D.L.
Hommer, D.; *see* Gordon, C.T.
Hong, W.; *see* Gordon, C.T.
Hope, D.A.; *see* Penn, D.L.
Horvitz-Lennon, M.; *see* Weiden, P.
Huttunen, M.O.; *see* Mednick, S.A.

I

Iacono, W.G.; *see* Grove, W.M.
Ingraham, L.J.; *see* Frenkel, E.; Kugelmass, S.; Mirsky, A.F.
Ingraham, L.J.; Kugelmass, S.; Frenkel, E.; Nathan, M.; and Mirsky, A.F. Twenty-five-year followup of the Israeli High-Risk Study: Current and lifetime psychopathology, 21(2):183–192, 1995.

J

Jin, Y.; Potkin, S.G.; and Sandman, C. Clozapine increases EEG photic driving in clinical responders, 21(2):263–268, 1995.
Jobe, T.H.; Harrow, M.; Martin, E.M.; Whitfield, H.J.; and Sands, J.R. Schizophrenic deficits: Neuroleptics and the prefrontal cortex, 20(3):413–416, 1994.
Johns, C.A., and Thompson, J.W. Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy, 21(4):607–619, 1995.

Jongbloet, P.H.; *see* Pallast, E.G.M.
Jordan, J.C. First person account: Schizophrenia—Adrift in an anchorless reality, 21(3):501–503, 1995.

K

Kagigebi, A. First person account: Living in a nightmare, 21(1):155–159, 1995.
Kahn, R.S.; *see* Amin, F.
Kane, J.M. Response to Fuchs (Letter to the Editor), 20(1):23–24, 1994.
Kane, J.M.; *see* Umbricht, D.
Kaysen, D.; *see* Gordon, C.T.
Keilp, J.G.; *see* Cornblatt, B.A.
Keller, A.B.; *see* Coursey, R.D.
Kendler, K.S., and Walsh, D. Schizotypal personality disorder in parents and the risk for schizophrenia in siblings, 21(1):47–52, 1995.
Kennedy, J.L.; *see* Barr, C.L.
Kidd, J.R.; *see* Barr, C.L.
Kidd, K.K.; *see* Barr, C.L.
Kim, D.; *see* Raine, A.
Knott, P.J.; *see* Amin, F.
Koch, P.A.M.; *see* Boumans, C.E.
Korfine, L.; *see* Lenzenweger, M.F.
Kornblith, S.J.; *see* Hogarty, G.E.
Krag, P.; *see* Ferstl, R.
Kremen, W.S.; Seidman, L.J.; Pepple, J.R.; Lyons, M.J.; Tsuang, M.T.; and Faraone, S.V. Neuropsychological risk indicators for schizophrenia: A review of family studies, 20(1):103–119, 1994.
Kring, A.M.; *see* Blanchard, J.J.
Kropp, S.; *see* Barry, K.L.
Kugelmass, S.; *see* Frenkel, E.; Ingraham, L.J.; Mirsky, A.F.
Kugelmass, S.; Faber, N.; Ingraham, L.J.; Frenkel, E.; Nathan, M.; Mirsky, A.F.; and Shakhar, G.B. Reanalysis of SCOR and anxiety measures in the Israeli High-Risk Study, 21(2):205–217, 1995.
Kurz, M.; *see* Meise, U.

L

Lamberti, J.S.; *see* Herz, M.I.
Lapierre, D.; Braun, C.M.J.; Hodgins, S.; Toupin, J.; Léveillée, S.; and Constantineau, C. Neuropsychological correlates of violence in schizophrenia, 21(2):253–262, 1995.
Leadbetter, R.A.; Shutty, M.S., Jr.; Higgins, P.B.; and Pavalonis, D. Multidisciplinary approach to psychosis, intermittent hyponatremia, and polydipsia, 20(2):375–385, 1994.
Leaf, P.; *see* Rosenheck, R.
Lehman, A.F. Vocational rehabilitation in schizophrenia, 21(4):645–656, 1995; *see also* Dixon, L.B.
Lehman, A.F.; Carpenter, W.T., Jr.; Goldman, H.H.; and Steinwachs, D.M. Treatment outcomes in schizophrenia: Implications for practice, policy, and research, 21(4):669–675, 1995.
Lehman, A.F.; Thompson, J.W.; Dixon, L.B.; and Scott, J.E. Schizophrenia: Treatment outcomes research—Editors' introduction, 21(4):561–566, 1995.
Lencz, T.; *see* Raine, A.
Lenzenweger, M.F. Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: An update, 20(1):121–135, 1994.
Lenzenweger, M.F., and Korfine, L. Perceptual aberrations, schizotypy, and the Wisconsin Card Sorting Test, 20(2):345–357, 1994.
Lerner, V.; Fotyanov, M.; Liberman, M.; Shlafman, M.; and Bar-El, Y. Maintenance medication for schizophrenia and schizoaffective patients, 21(4):693–701, 1995.
Léveillée, S.; *see* Lapierre, D.
Levine, J.; *see* Dixon, L.B.
Levinson, D.F.; *see* Gladis, M.M.
Levy, D.L.; Holzman, P.S.; Matthysse, S.; and Mendell, N.R. Eye tracking and schizophrenia: A selective review, 20(1):47–62, 1994.
Lewine, R.R.J. Sex: An imperfect marker of gender, 20(4):777–779, 1994.
Liberman, M.; *see* Lerner, V.
Lichtermann, D.; *see* Maier, W.
Lidsky, T.I. Reevaluation of the mesolimbic hypothesis of antipsychotic drug action, 21(1):67–74, 1995.
Lieberman, J.A.; *see* Shore, D.
Lyons, M.J.; *see* Kremen, W.S.

M

MacDonald, A.W. III; *see* Harrow, M.
Machón, R.A.; *see* Mednick, S.A.
Maier, W.; Lichtermann, D.; Minges, J.; and Heun, R. Personality disorders among the relatives of schizophrenia patients, 20(3):481–493, 1994.
Malla, A.K.; *see* Norman, R.M.G.
Marco, E.; *see* Cannon, T.D.
Marder, S.R.; see Kane, J.M.
Marengo, J. Classifying the courses of schizophrenia, 20(3):519–536, 1994; *see also* Harrow, M.
Markow, T.; *see* Benedict, R.H.B.
Marsh, J.T.; *see* Strandburg, R.J.
Martin, E.M.; *see* Jobe, T.H.
Martin, M.; *see* Remschmidt, H.E.
Martin, P., and Albers, M. Cerebellum and schizophrenia: A selective review, 21(2):241–250, 1995.
Matthews, S.; *see* Shore, D.
Matthysse, S.; *see* Levy, D.L.
Maurer, K.; *see* Riecher-Rössler, A.
McClellan, J.M.; *see* Werry, J.S.
McCormick, J.A.; *see* Benedict, R.H.B.
McGlashan, T.H.; *see* Hoffman, R.E.

McKee, D.; *see* Barry, K.L.
McKenna, K.; *see* Gordon, C.T.
McNeil, T.F.; *see* Torrey, E.F.
Mednick, S.A.; Huttunen, M.O.; and Machón, R.A. Prenatal influenza infections and adult schizophrenia, 20(2):263–267, 1994.
Meeks, S., and Murrell, S.A. Service providers in the social networks of clients with severe mental illness, 20(2):399–406, 1994.
Meise, U.; *see* Riecher-Rössler, A.
Meise, U.; Kurz, M.; and Fleischhacker, W.W. Antipsychotic maintenance treatment of schizophrenia patients: Is there a consensus?, 20(1):215–225, 1994.
Mendell, N.R.; *see* Levy, D.L.
Miklowitz, D.J. Family risk indicators in schizophrenia, 20(1):137–149, 1994.
Miller, A.L.; *see* Dassori, A.M.
Milstein, R.; *see* Rosenheck, R.
Minges, J.; *see* Maier, W.
Mirsky, A.F. Israeli High-Risk Study: Editor's introduction, 21(2):179–182, 1995; *see also* Ingraham, L.J.; Kugelmass, S.
Mirsky, A.F.; Ingraham, L.J.; and Kugelmass, S. Neuropsychological assessment of attention and its pathology in the Israeli cohort, 21(2):193–204, 1995.
Mirsky, A.F.; Kugelmass, S.; Ingraham, L.J.; Frenkel, E.; and Nathan, M. Overview and summary: Twenty-five-year followup of high-risk children, 21(2):227–239, 1995.
Moldin, S.O. Indicators of liability to schizophrenia: Perspectives from genetic epidemiology, 20(1):169–184, 1994.
Moldin, S.O., and Erlenmeyer-Kimling, L. Measuring liability to schizophrenia: Progress report 1994: Editors' introduction, 20(1):25–29, 1994.
Molinaro, M.; *see* Mueser, K.T.
Mott, T.; *see* Weiden, P.
Mowry, B.J.; *see* Gladis, M.M.
Mueser, K.T.; *see* Penn, D.L.
Mueser, K.T.; Nishith, P.; Tracy, J.I.; DeGirolamo, J.; and Molinaro, M. Expectations and motives for substance use in schizophrenia, 21(3):367–389, 1995.
Müller, U.; *see* Wiedemann, G.
Murray, R.M.; *see* Castle, D.J.
Murrell, S.A.; *see* Meeks, S.
Myers, C.P.; *see* Thompson, J.W.

N

Nathan, M.; *see* Frenkel, E.; Ingraham, L.J.; Kugelmass, S.; Mirsky, A.F.
Neale, J.M.; *see* Blanchard, J.J.
Neale, M.; *see* Rosenheck, R.
Newcomer, J.W.; *see* Csernansky, J.G.
Nishith, P.; *see* Mueser, K.T.
Norman, R.M.G., and Malla, A.K. Prodromal symptoms of relapse in schizophrenia: A review, 21(4):527–539, 1995.
Nuechterlein, K.H.; *see* Benedict, R.H.B.

O

Olfson, M.; *see* Weiden, P.J.

P

Pakstis, A.J.; *see* Barr, C.L.
Pallast, E.G.M.; Jongbloet, P.H.; Straatman, H.M.; and Zielhuis, G.A. Excess seasonality of births among patients with schizophrenia and seasonal ovopathy, 20(2):269–276, 1994.
Pavalonis, D.; *see* Leadbetter, R.A.
Penn, D.L.; Guynan, K.; Daily, T.; Spaulding, W.D.; Garbin, C.P.; and Sullivan, M. Dispelling the stigma of schizophrenia: What sort of information is best?, 20(3):567–578, 1994.
Penn, D.L.; Mueser, K.T.; Spaulding, W.; Hope, D.A.; and Reed, D. Information processing and social competence in chronic schizophrenia, 21(2):269–281, 1995.
Pepple, J.R.; *see* Kremen, W.S.
Peralta, V.; *see* Cuesta, M.J.
Phelps, J.A.; *see* Davis, J.O.
Potkin, S.G.; *see* Jin, Y.
Powchik, P.; *see* Davidson, M.
Priebe, S., and Gruyters, T. Patients' assessment of treatment predicting outcome, 21(1):87–94, 1995.

Q

Quinn, P.O.; *see* Torrey, E.F.

R

Raine, A.; Reynolds, C.; Lencz, T.; Scerbo, A.; Triphon, N.; and Kim, D. Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality, 20(1):191–201, 1994.
Rapkin, B.; *see* Weiden, P.
Rapoport, J.L.; *see* Gordon, C.T.
Rawlings, R.R.; *see* Torrey, E.F.
Reed, D.; *see* Penn, D.L.
Reiss, D.; *see* Hogarty, G.E.
Remschmidt, H.E.; Schulz, E.; Martin, M.; Warnke, A.; and Trott, G.-E. Childhood-onset schizophrenia: History of the concept and recent studies, 20(4):727–745, 1994.
Reynolds, C.; *see* Raine, A.
Rice, J.P., and Todorov, A.A. Stability of diagnosis: Application to phenotype definition, 20(1):185–190, 1994.
Rickler, K.; *see* Torrey, E.F.
Riecher-Rössler, A.; Häfner, H.; Stumbaum, M.; Maurer, K.; and Schmidt, R. Can estradiol modulate schizophrenic symptomatology?, 20(1):203–214, 1994.
Riecher-Rössler, A.; Rössler, W.; Förstl, H.; and Meise, U. Late-onset schizophrenia and late paraphrenia, 21(3):345–354, 1995.

Romney, D.M. Psychosocial functioning and subjective experience in schizophrenia: A reanalysis, 21(3):405–410, 1995.

Rosenheck, R.; Neale, M.; Leaf, P.; Milstein, R.; and Frisman, L. Multisite experimental cost study of intensive psychiatric community care, 21(1):129–140, 1995.

Rössler, W.; *see* Riecher-Rössler, A.

Russell, A.T. The clinical presentation of childhood-onset schizophrenia, 20(4):631–646, 1994.

S

Sachdev, P. The epidemiology of drug-induced akathisia. Part I. Acute akathisia, 21(3):431–449, 1995; The epidemiology of drug-induced akathisias. Part II. Chronic, tardive, and withdrawal akathisia, 21(3):451–461, 1995.

Saldana, D.; *see* Dassori, A.M.

Sandman, C.; *see* Jin, Y.

Sands, J.R.; *see* Harrow, M.; Jobe, T.H.

Satz, P.; *see* Green, M.F.

Savoie, T.; *see* Walker, E.F.

Scerbo, A.; *see* Raine, A.

Schmeidler, J.; *see* Amin, F.

Schmidt, R.; *see* Riecher-Rössler, A.

Schulz, E.; *see* Remschmidt, H.E.

Scott, J.E.; *see* Lehman, A.F.

Scott, J.E., and Dixon, L.B. Assertive community treatment and case management for schizophrenia, 21(4):657–668, 1995; Psychological interventions for schizophrenia, 21(4):621–630, 1995.

Seidman, L.J.; *see* Kremen, W.S.

Serper, M.R., and Harvey, P.D. The need to integrate neuropsychological and experimental schizophrenia research, 20(1):1–11, 1994.

Servan-Schreiber, D.; *see* Cohen, J.D.

Sewell, K.W.; *see* Tam, W.-C.C.

Shakhar, G.B.; *see* Kugelmass, S.

Sherman, T.; *see* Asarnow, R.F.

Shlafman, M.; *see* Lerner, V.

Shore, D.; Matthews, S.; Cott, J.; and Lieberman, J.A. NIMH activities: Clinical implications of clozapine discontinuation: Report of an NIMH workshop, 21(2): 333–338, 1995.

Shutty, M.S., Jr.; *see* Leadbetter, R.A.

Silverstein, M.L.; *see* Harrow, M.

Simmons, J.Q. III; *see* Baltaxe, C.A.M.

Sjostrom, K.; *see* Torrey, E.F.

Smeraldi, E.; *see* Battaglia, M.

Spaulding, W.D.; *see* Penn, D.L.

Spencer, E.K., and Campbell, M. Children with schizophrenia: Diagnosis, phenomenology, and pharmacotherapy, 20(4):713–725, 1994.

Squires-Wheeler, E.; *see* Friedman, D.

Stanton, J.M. Weight gain associated with neuroleptic medication: A review, 21(3):463–472, 1995.

Steinwachs, D.M.; *see* Lehman, A.F.

Stern, R.; *see* Amin, F.

Straatman, H.M.; *see* Pallast, E.G.M.

Strandburg, R.J.; Marsh, J.T.; Brown, W.S.; Asarnow, R.F.; and Guthrie, D. Information-processing deficits across childhood- and adult-onset schizophrenia, 20(4):685–695, 1994.

Strauss, M.E., and Summerfelt, A. Response to Serper and Harvey, 20(1):13–21, 1994.

Stumbaum, M.; *see* Riecher-Rössler, A.

Sullivan, M.; *see* Penn, D.L.

Summerfelt, A.; *see* Strauss, M.E.

T

Takei, N.; *see* Castle, D.J.

Takizawa, Y.; *see* Wada, Y.

Tam, W.-C.C., and Sewell, K.W. Seasonality of birth in schizophrenia in Taiwan, 21(1):117–127, 1995.

Taylor, E.H.; *see* Torrey, E.F.

Thompson, J.W.; *see* Johns, C.A.; Lehman, A.F.

Thompson, J.W.; Belcher, J.R.; DeForge, B.R.; Myers, C.P.; and Henderson, M.J. Trends in the inpatient care of persons with schizophrenia, 21(1):75–85, 1995.

Todorov, A.A.; *see* Rice, J.P.

Tompson, M.C.; *see* Asarnow, J.R.

Toomey, R.; *see* Corrigan, P.W.

Torrey, E.F.; Taylor, E.H.; Bracha, H.S.; Bowler, A.E.; McNeil, T.F.; Rawlings, R.R.; Quinn, P.O.; Bigelow, L.B.; Rickler, K.; Sjostrom, K.; Higgins, E.S.; and Gottesman, I.I. Prenatal origin of schizophrenia in a subgroup of discordant monozygotic twins, 20(3):423–432, 1994.

Torrey, E.F., and Yolken, R.H. Could schizophrenia be a viral zoonosis transmitted from house cats?, 21(2):167–171, 1995.

Toupin, J.; *see* Lapierre, D.

Tracy, J.I.; *see* Mueser, K.T.

Triphon, N.; *see* Raine, A.

Trott, G.-E.; *see* Remschmidt, H.E.

Tsuang, M.T.; *see* Kremen, W.S.

U

Ulrich, R.; *see* Hogarty, G.E.

Umbricht, D., and Kane, J.M. Risperidone: Efficacy and safety, 21(4):593–606, 1995.

V

van't Hof, M.A.; *see* Boumans, C.E.

van den Bosch, R.J.; *see* Vollema, M.G.

Vollema, M.G., and van den Bosch, R.J. The multidimensionality of schizotypy, 21(1):19–31, 1995.

W

Wada, Y.; Takizawa, Y.; and

Yamaguchi, N. Abnormal photic driving responses in never-medicated schizophrenia patients, 21(1):111–115, 1995.
Wahlstrom, J.; *see* DeLisi, L.E.
Walker, E.F. Developmentally moderated expressions of the neuropathology underlying schizophrenia, 20(3):453–480, 1994.
Walker, E.F.; Savoie, T.; and Davis, D. Neuromotor precursors of schizophrenia, 20(3):441–451, 1994.
Walkup, J. A clinically based rule of thumb for classifying delusions, 21(2):323–331, 1995.
Walsh, D.; *see* Kendler, K.S.
Waltrip, R.W. II. Evaluation of Torrey and Yolken's feline viral zoonosis theory of schizophrenia, 21(2):173–178, 1995.
Warner, R. Time trends in schizophrenia: Changes in obstetric risk factors with industrialization, 21(3):483–500, 1995.
Warnke, A.; *see* Remschmidt, H.E.
Watkins, J.M.; *see* Asarnow, R.F.
Weiden, P.; Rapkin, B.; Mott, T.; Zygmunt, A.; Goldman, D.; Horvitz-Lennon, M.; and Frances, A. Rating of medication influences (ROMI) scale in schizophrenia, 20(2):297–310, 1994.
Weiden, P.J., and Olfson, M. Cost of relapse in schizophrenia, 21(3):419–429, 1995.
Werry, J.S.; McClellan, J.M.; Andrews, L.K.; and Ham, M. Clinical features and outcome of child and adolescent schizophrenia, 20(4):619–630, 1994.
Wetterberg, L.; *see* Barr, C.L.
Whitfield, H.J.; *see* Jobe, T.H.
Widlak, P.; *see* Barry, K.L.
Wiedemann, G.; Hahlweg, K.; Hank, G.; Feinstein, E.; Müller, U.; and Dose, M. Deliverability of psychoeducational family management, 20(3):547–556, 1994.
Williams, M.E.; *see* Asarnow, R.F.
Winefield, H.R., and Harvey, E.J. Needs of family caregivers in chronic schizophrenia, 20(3):557–566, 1994.

Y

Yamaguchi, N.; *see* Wada, Y.
Yolken, R.H.; *see* Torrey, E.F.
Yonan, C.A.; *see* Harrow, M.

Z

Zahn, T.; *see* Gordon, C.T.
Zametkin, A.; *see* Gordon, C.T.
Zielhuis, G.A.; *see* Pallast, E.G.M.
Zitman, F.G.; *see* Boumans, C.E.
Zygmunt, A.; *see* Weiden, P.

Subject Index

A

Adolescence

Childhood-onset schizophrenia: History of the concept and recent studies, 20:727
Clinical features and outcome of child and adolescent schizophrenia, 20:619
Locus of control and mental health in adolescence, 21:219
Speech and language disorders in children and adolescents with schizophrenia, 21:677

Adult onset

Commentary to "Late-onset schizophrenia and late paraphrenia," 21:355
Information-processing deficits across childhood- and adult-onset schizophrenia, 20:685
Late-onset schizophrenia and late paraphrenia, 21:345

Affective deficits and social deficits

Family risk indicators in schizophrenia, 20:137
Flat affect in schizophrenia: A test of neuropsychological models, 20:311
Vulnerability to delusions over time in schizophrenia and affective disorders, 21:95

Age factors

Age at onset in subtypes of schizophrenic disorders, 20:287
Childhood-onset schizophrenia: Editors' introduction, 20:591
Childhood-onset schizophrenia: History of the concept and recent studies, 20:727
Commentary to "Late-onset schizophrenia and late paraphrenia," 21:355
Communication deficits in childhood schizophrenia spectrum

disorders, 20:671
Information-processing deficits across childhood- and adult-onset schizophrenia, 20:685
Late-onset schizophrenia and late paraphrenia, 21:345
Neuromotor precursors of schizophrenia, 20:441
Speech and language disorders in children and adolescents with schizophrenia, 21:677

Akathisia

The epidemiology of drug-induced akathisia: Part I. Acute akathisia, 21:431
The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias, 21:451

Akinesia

Depression in schizophrenia: Are neuroleptics, akinesia, or anhedonia involved?, 20:327

Amyotrophic lateral sclerosis

Medical conditions in Ashkenazi schizophrenic pedigrees, 20:507

Anhedonia

Depression in schizophrenia: Are neuroleptics, akinesia, or anhedonia involved?, 20:327

Antipsychotic drugs. *See also* Neuroleptics

Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy, 21:607
Antipsychotic maintenance treatment of schizophrenia patients: Is there a consensus?, 20:215
Clozapine: Benefits and risks, 20:23
Clozapine: Efficacy and safety, 21:579
Risperidone: Efficacy and safety, 21:593

Artificial intelligence

Schizophrenic deficits: Neuroleptics and the prefrontal cortex, 20:413

Attention dysfunctions

Effects of attention training on information processing in schizophrenia, 20:537
Impaired attention, genetics, and the pathophysiology of schizophrenia, 20:31
Neuropsychological assessment of attention and its pathology in the Israeli cohort, 21:193
Response to Fuchs, 20:23

B

Basal ganglia

Reevaluation of the mesolimbic hypothesis of antipsychotic drug action, 21:67

Behavior

Cognitive/neuropsychological studies of children with a schizophrenic disorder, 20:647
Deliverability of psychoeducational family management, 20:547
Developmentally moderated expressions of the neuropathology underlying schizophrenia, 20:453
Family interventions for schizophrenia, 21:631
Multidisciplinary approach to psychosis, intermittent hyponatremia, and polydipsia, 20:375

Bipolar disorder

Minor physical anomalies in schizophrenia patients, bipolar patients, and their siblings, 20:433

Bivariate phenotype

Indicators of liability to schizophrenia: Perspectives from genetic epidemiology, 20:169

Brain morphology. *See also* Structural brain abnormalities

Cognitive/neuropsychological studies of children with a schizophrenic disorder, 20:647
Schizophrenic deficits: Neuroleptics and the prefrontal cortex, 20:413
Structural brain abnormalities as indicators of vulnerability to schizophrenia, 20:89

C

Candidate genes

Medical conditions in Ashkenazi schizophrenic pedigrees, 20:507

Caregivers

Needs of family caregivers in chronic schizophrenia, 20:557
Service providers in the social networks of clients with severe mental illness, 20:399

Cerebellar-limbic projections

Cerebellum and schizophrenia: A selective review, 21:241

Cerebellum

Cerebellum and schizophrenia: A selective review, 21:241

Childhood onset. *See also* Age factors

Childhood-onset schizophrenia: A followup study, 20:599
Childhood-onset schizophrenia: An NIMH study in progress, 20:697
Childhood-onset schizophrenia: Editors' introduction, 20:591
Childhood-onset schizophrenia: History of the concept and recent studies, 20:727
Children with schizophrenia: Diagnosis, phenomenology, and pharmacotherapy, 20:713
Clinical features and outcome of child and adolescent schizo-

phrenia, 20:619
The clinical presentation of childhood-onset schizophrenia, 20:631
Cognitive/neuropsychological studies of children with a schizophrenic disorder, 20:647
Communication deficits in childhood schizophrenia spectrum disorders, 20:671
Information-processing deficits across childhood- and adult-onset schizophrenia, 20:685
Speech and language disorders in children and adolescents with schizophrenia, 21:677

Classification

Childhood-onset schizophrenia: Editors' introduction, 20:591
Classifying the courses of schizophrenia, 20:519
A clinically based rule of thumb for classifying delusions, 21:323

Clinical features

Clinical features and outcome of child and adolescent schizophrenia, 20:619

Clozapine

Clinical implications of clozapine discontinuation: Report of an NIMH workshop, 21:333
Clozapine: Benefits and risks, 20:23
Clozapine: Efficacy and safety, 21:579
Clozapine increases EEG photic driving in clinical responders, 21:263
Reevaluation of the mesolimbic hypothesis of antipsychotic drug action, 21:67
Response to Fuchs, 20:23
Weight gain associated with neuroleptic medication: A review, 21:463

Cognition

Cognitive/neuropsychological studies of children with a schizophrenic disorder, 20:647
Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality, 20:191
Communication deficits in childhood schizophrenia spectrum disorders, 20:671
Event-related potentials as indicators of risk for schizophrenia, 20:63
Information-processing deficits across childhood- and adult-onset schizophrenia, 20:685
Interpersonal problem solving and information processing in schizophrenia, 21:395
The need to integrate neuropsychological and experimental schizophrenia research, 20:1
Response to Serper and Harvey, 20:13
Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

Cognitive rehabilitation and retraining

Effects of attention training on information processing in schizophrenia, 20:537

Communication deviance

Communication deficits in childhood schizophrenia spectrum disorders, 20:671
Expressed emotion and language disturbances in parents of stable schizophrenia patients, 21:411
Family risk indicators in schizophrenia, 20:137
Speech and language disorders in children and adolescents with schizophrenia, 21:677

Community care

Assertive community treatment and case management for schizophrenia, 21:657
Multisite experimental cost study of intensive psychiatric community care, 21:129

Computer simulation models

Schizophrenic deficits: Neuroleptics and the prefrontal cortex, 20:413

Computerized imaging. *See also* Magnetic resonance imaging

Cerebellum and schizophrenia: A selective review, 21:241

Connectionism

The need to integrate neuropsychological and experimental schizophrenia research, 20:1
Schizophrenic deficits: Neuroleptics and the prefrontal cortex, 20:413
Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

Continuous Performance Test

Impaired attention, genetics, and the pathophysiology of schizophrenia, 20:31
Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

Cortical pruning

Dysmodularity: A neurocognitive model for schizophrenia, 20:249

Corticocortical connectivity

Corticocortical connectivity, autonomous networks, and schizophrenia, 20:257

Cost of illness

Cost of relapse in schizophrenia, 21:419
Costs of schizophrenia in The Netherlands, 21:141
Multisite experimental cost study of intensive psychiatric community care, 21:129
Seasonality of birth in schizo-

phrenia in Taiwan, 21:117

Course and outcome. *See also* Long-term followback; Longitudinal data; Statistical issues

Childhood-onset schizophrenia: A followup study, 20:599
Childhood-onset schizophrenia: History of the concept and recent studies, 20:727
Clinical features and outcome of child and adolescent schizophrenia, 20:619
Patients' assessment of treatment predicting outcome, 21:87
Schizophrenia: Treatment outcomes research—Editors' introduction, 21:561
Treatment outcomes in schizophrenia: Implications for practice, policy, and research, 21:669

Cultural factors

Schizophrenia among Hispanics: Epidemiology, phenomenology, course, and outcome, 21:303
Time trends in schizophrenia: Changes in obstetric risk factors with industrialization, 21:483

D

Debrisoquine plasma

Assessment of the central dopaminergic index of plasma HVA in schizophrenia, 21:53

Delusions

The clinical presentation of childhood-onset schizophrenia, 20:631
A clinically based rule of thumb for classifying delusions, 21:323
Delusions in schizophrenia spectrum disorders: Diagnostic issues, 20:747
Vulnerability to delusions over time in schizophrenia and affective disorders, 21:95

Demographic factors. *See also* Cultural factors

Age at onset in subtypes of schizophrenic disorders, 20:287

Depression

Depression in schizophrenia: Are neuroleptics, akinesia, or anhedonia involved?, 20:327
First person account: Insight from a schizophrenia patient with depression, 21:703

Dermatoglyphics

Prenatal development of monozygotic twins and concordance for schizophrenia, 21:357
Prenatal origin of schizophrenia in a subgroup of discordant monozygotic twins, 20:423

Diagnosis

Childhood-onset schizophrenia: Editors' introduction, 20:591
Children with schizophrenia: Diagnosis, phenomenology, and pharmacotherapy, 20:713
Clinical features and outcome of child and adolescent schizophrenia, 20:619
The clinical presentation of childhood-onset schizophrenia, 20:631
Delusions in schizophrenia spectrum disorders: Diagnostic issues, 20:747
Stability of diagnosis: Application to phenotype definition, 20:185

Diagnostic stability

Stability of diagnosis: Application to phenotype definition, 20:185

Disorganized thinking subtype

Age at onset in subtypes of schizophrenic disorders, 20:287
Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality, 20:191
Communication deficits in childhood schizophrenia spectrum disorders, 20:671
Expressed emotion and language disturbances in parents of stable schizophrenia patients, 21:411

Dopamine

Are there neurochemical indicators of risk for schizophrenia?, 20:75
Assessment of the central dopaminergic index of plasma HVA in schizophrenia, 21:53
Can estradiol modulate schizophrenic symptomatology?, 20:203
Developmentally moderated expressions of the neuropathology underlying schizophrenia, 20:453
Schizophrenic deficits: Neuroleptics and the prefrontal cortex, 20:413
Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

Dosage considerations

Antipsychotic maintenance treatment of schizophrenia patients: Is there a consensus?, 20:215
Conventional antipsychotic medications for schizophrenia, 21:567

Drug-naive patients

Abnormal photic driving responses in never-medicated schizophrenia patients, 21:111

E

Economic factors

Time trends in schizophrenia: Changes in obstetric risk factors with industrialization, 21:483

Electroencephalography

Clozapine increases EEG photic driving in clinical responders, 21:263

Electroconvulsive therapy

Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy, 21:607

Epidemiology

Can estradiol modulate schizophrenic symptomatology?, 20:203
Could schizophrenia be a viral zoonosis transmitted from house cats?, 21:167
The epidemiology of drug-induced akathisia: Part I. Acute akathisia, 21:431
The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias, 21:451
Evaluation of Torrey and Yolken's feline viral zoonosis theory of schizophrenia, 21:173
Geographic correlation of schizophrenia to ticks and tick-borne encephalitis, 20:755
Schizophrenia among Hispanics: Epidemiology, phenomenology, course, and outcome, 21:303
Time trends in schizophrenia: Changes in obstetric risk factors with industrialization, 21:483

Estradiol

Can estradiol modulate schizophrenic symptomatology?, 20:203

Etiology

Childhood-onset schizophrenia: History of the concept and recent studies, 20:727
Excess seasonality of births among patients with schizophrenia and seasonal ovopathy, 20:269
Lack of insight in schizophrenia, 20:359
Measuring liability to schizophrenia: Progress report 1994: Editors' introduction, 20:25
Prenatal origin of schizophrenia in a subgroup of discordant monozygotic twins, 20:423

Event-related potentials

Event-related potentials as indicators of risk for schizophrenia, 20:63
Information-processing deficits across childhood- and adult-onset schizophrenia, 20:685

Experimental psychopathology

Measuring liability to schizophrenia: Progress report 1994: Editors' introduction, 20:25

Expressed emotion

Expressed emotion and language disturbances in parents of stable schizophrenia patients, 21:411
Family risk indicators in schizophrenia, 20:137

Eye movement studies

Comment on Levy et al. "Eye tracking dysfunction and schizophrenia," 20:781
Eye tracking and schizophrenia: A selective review, 20:47

F

Factor analysis

The multidimensionality of schizotypy, 21:19

Families

Deliverability of psychoeducational family management, 20:547
Family interventions for schizophrenia, 21:631
First person account: Life with a mentally ill spouse, 20:227
Needs of family caregivers in chronic schizophrenia, 20:557

Family studies. *See also* Twin studies

Delusions in schizophrenia spectrum disorders: Diagnostic issues, 20:747
Family risk indicators in schizophrenia, 20:137
A family study of schizotypal disorder, 21:33
Indicators of liability to schizophrenia: Perspectives from genetic epidemiology, 20:169
Measuring liability to schizophrenia: Progress report 1994: Editors' introduction, 20:25
Neuropsychological risk indicators for schizophrenia: A review of family studies, 20:103
Personality disorders among the relatives of schizophrenia patients, 20:481
Schizotypal personality disorder in parents and the risk for schizophrenia in siblings, 21:47
Structural brain abnormalities as indicators of vulnerability to schizophrenia, 20:89

Felines

Could schizophrenia be a viral zoonosis transmitted from house cats?, 21:167
Evaluation of Torrey and Yolken's feline viral zoonosis theory of schizophrenia, 21:173

First-episode psychosis

Age at onset in subtypes of schizophrenic disorders, 20:287
Clinical features and outcome of child and adolescent schizophrenia, 20:619

Flat affects

The clinical presentation of childhood-onset schizophrenia, 20:631
Flat affect in schizophrenia: A test of neuropsychological models, 20:311

Frontal cortex

Neuropsychological correlates of

violence in schizophrenia, 21:253
Schizophrenic deficits: Neuroleptics and the prefrontal cortex, 20:413
Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

G

Gain

Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

Gender differences

Age at onset in subtypes of schizophrenic disorders, 20:287
Gender differences in schizophrenia: Hormonal effect or subtypes?, 21:1
Linkage study of a susceptibility locus for schizophrenia in the pseudoautosomal region, 20:277
Sex: An imperfect marker of gender, 20:777
Trends in the inpatient care of persons with schizophrenia, 21:75

Genetic epidemiology

Indicators of liability to schizophrenia: Perspectives from genetic epidemiology, 20:169

Genetic factors. *See also* Etiology; Family studies

Are there neurochemical indicators of risk for schizophrenia?, 20:75
Comment on Levy et al. "Eye tracking dysfunction and schizophrenia," 20:781
Delusions in schizophrenia spectrum disorders: Diagnostic issues, 20:747
A family study of schizotypal disorder, 21:33
Impaired attention, genetics, and the pathophysiology of schizophrenia, 20:31
Linkage study of a susceptibility locus for schizophrenia in the pseudoautosomal region, 20:277
Medical conditions in Ashkenazi schizophrenic pedigrees, 20:507
Schizophrenia and sex chromosome anomalies, 20:495
Schizotypal personality disorder in parents and the risk for schizophrenia in siblings, 21:47
Stability of diagnosis: Application to phenotype definition, 20:185
Structural brain abnormalities as indicators of vulnerability to schizophrenia, 20:89
Twins with schizophrenia: Genes or germs?, 21:13

Grants

Schizophrenia-related grants, fiscal year 1993, 20:787
Schizophrenia-related grants, fiscal year 1995, 21:505

H

Hallucinations

The clinical presentation of childhood-onset schizophrenia, 20:631

Haloperidol

Children with schizophrenia: Diagnosis, phenomenology, and pharmacotherapy, 20:713

Handedness

Twins with schizophrenia: Genes or germs?, 21:13

Hematologic cancers

Medical conditions in Ashkenazi schizophrenic pedigrees, 20:507

High-risk studies

Neuropsychological risk indicators for schizophrenia: A review of family studies, 20:103
Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: An update, 20:121
Single indicator of risk for schizophrenia: Probable fact or likely myth?, 20:151

Hispanics

Schizophrenia among Hispanics: Epidemiology, phenomenology, course, and outcome, 21:303

History of schizophrenia

The need to integrate neuropsychological and experimental schizophrenia research, 20:1

Hormones

Can estradiol modulate schizophrenic symptomatology?, 20:203

Hospitalization

Assertive community treatment and case management for schizophrenia, 21:657
Patients' assessment of treatment predicting outcome, 21:87
Trends in the inpatient care of persons with schizophrenia, 21:75

Homovanillic acid

Assessment of the central dopaminergic index of plasma HVA in schizophrenia, 21:53

Hyponatremia

Multidisciplinary approach to psychosis, intermittent hyponatremia, and polydipsia, 20:375

I

Immigration

Time trends in schizophrenia: Changes in obstetric risk factors with industrialization, 21:483

Infections. *See also* Prenatal infections; Viral infections

Geographic correlation of schizophrenia to ticks and tick-borne encephalitis, 20:755

Influenza

Gender differences in schizophrenia: Hormonal effect or subtypes?, 21:1
Prenatal influenza infections and adult schizophrenia, 20:263

Information processing. *See also* Cognition

Effects of attention training on information processing in schizophrenia, 20:537
Information processing and social competence in chronic schizophrenia, 21:269
Interpersonal problem solving and information processing in schizophrenia, 21:395

Inpatient care

Trends in the inpatient care of persons with schizophrenia, 21:75

Interpersonal relations

Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality, 20:191
Interpersonal problem solving and information processing in schizophrenia, 21:395

Israel

Israeli High-Risk Study: Editor's introduction, 21:179
Locus of control and mental health in adolescence, 21:219
Neuropsychological assessment of attention and its pathology in the Israeli cohort, 21:193
Overview and summary: Twenty-five-year followup of high-risk children, 21:227
Reanalysis of SCOR and anxiety measures in the Israeli High-Risk Study, 21:205
Twenty-five-year followup of the Israeli High-Risk Study: Current and lifetime psychopathology, 21:183

L

Language

Expressed emotion and language disturbances in parents of stable schizophrenia patients, 21:411
Speech and language disorders in children and adolescents with schizophrenia, 21:677

Late-onset schizophrenia. *See also* Adult onset

Commentary to "Late-onset schizophrenia and late paraphrenia," 21:355
Late-onset schizophrenia and late paraphrenia, 21:345

Liability. *See* Risk for schizophrenia

Linkage studies

Delusions in schizophrenia spectrum disorders: Diagnostic issues, 20:747
Indicators of liability to schizophrenia: Perspectives from genetic epidemiology, 20:169
Linkage study of a susceptibility locus for schizophrenia in the pseudoautosomal region, 20:277
Personality disorders among the relatives of schizophrenia patients, 20:481

LISREL software program

Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality, 20:191
Psychosocial functioning and subjective experience in schizophrenia: A reanalysis, 21:405

Locus of control

Locus of control and mental health in adolescence, 21:219

Long-term followback

Classifying the courses of schizophrenia, 20:519
Vulnerability to delusions over time in schizophrenia and affective disorders, 21:95

Long-term treatment

Patients' assessment of treatment predicting outcome, 21:87

Longitudinal data

Classifying the courses of schizophrenia, 20:519
Israeli High-Risk Study: Editor's introduction, 21:179
Locus of control and mental health in adolescence and adulthood, 21:219
Twenty-five-year followup of the Israeli High-Risk Study: Current and lifetime psychopathology, 21:183
Vulnerability to delusions over time in schizophrenia and affective disorders, 21:95

Lysosomal enzyme disorders

Medical conditions in Ashkenazi schizophrenic pedigrees, 20:507

M

Magnetic resonance imaging

Structural brain abnormalities as indicators of vulnerability to schizophrenia, 20:89

Maintenance medication

Cost of relapse in schizophrenia, 21:419
Maintenance medication for schizophrenia and schizoaffective patients, 21:693

Medical geography. *See also* Demographic factors

Geographic correlation of schizophrenia to ticks and tick-borne encephalitis, 20:755
Role of selenium and other trace elements in the geography of schizophrenia, 20:387

Medicare and Medicaid

Trends in the inpatient care of persons with schizophrenia, 21:75

Medication effects

Clozapine: Efficacy and safety, 21:579

Conventional antipsychotic medications for schizophrenia, 21:567

Cost of relapse in schizophrenia, 21:419

Rating of medication influences (ROMI) scale in schizophrenia, 20:297

Risperidone: Efficacy and safety, 21:593

Role of selenium and other trace elements in the geography of schizophrenia, 20:387

Schizophrenic deficits: Neuroleptics and the prefrontal cortex, 20:413

Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

Medication noncompliance

Cost of relapse in schizophrenia, 21:419

Medication nonresponse

Cost of relapse in schizophrenia, 21:419

Menstrual cycle

Can estradiol modulate schizophrenic symptomatology?, 20:203

Mesolimbic dopamine system

Reevaluation of the mesolimbic hypothesis of antipsychotic drug action, 21:67

3-methoxy-4-hydroxyphenylglycol (MHPG)

Assessment of the central dopaminergic index of plasma HVA in schizophrenia, 21:53

Mixed model

Indicators of liability to schizophrenia: Perspectives from genetic epidemiology, 20:169

Modality-shift effect

Is the modality-shift effect specific for schizophrenia patients?, 20:367

Mood disorder

Clinical features and outcome of child and adolescent schizophrenia, 20:619

N

National Institute of Mental Health

Clinical implications of clozapine discontinuation: Report of an NIMH workshop, 21:333

Negative symptoms

Childhood-onset schizophrenia: History of the concept and recent studies, 20:727

The Netherlands

Costs of schizophrenia in The Netherlands, 21:141

Neural networks

Developmentally moderated expressions of the neuropathology underlying schizophrenia, 20:453

Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

Neurobehavioral functions

Cognitive/neuropsychological studies of children with a schizophrenic disorder, 20:647

Neurobiology

Childhood-onset schizophrenia: An NIMH study ir progress, 20:697

Neurocognition

Dysmodularity: A neurocognitive model for schizophrenia, 20:249

Neurodevelopmental abnormalities

Developmentally moderated expressions of the neuropathology underlying schizophrenia, 20:453

Minor physical anomalies in schizophrenia patients, bipolar patients, and their siblings, 20:433

Prenatal development of monozygotic twins and concordance for schizophrenia, 21:357

Prenatal origin of schizophrenia in a subgroup of discordant monozygotic twins, 20:423

Neurodynamics

Corticocortical connectivity, autonomous networks, and schizophrenia, 20:257

Dysmodularity: A neurocognitive model for schizophrenia, 20:249

Neuroleptics. *See also specific drugs by name*

Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy, 21:607

Antipsychotic maintenance treatment of schizophrenia patients: Is there a consensus?, 20:215

Childhood-onset schizophrenia: An NIMH study in progress, 20:697

Deliverability of psychoeducational family management, 20:547

Depression in schizophrenia: Are neuroleptics, akinesia, or anhedonia involved?, 20:327

The epidemiology of drug-induced akathisia: Part I. Acute akathisia, 21:431

The epidemiology of drug-induced akathisia: Part II.

Chronic, tardive, and withdrawal akathisias, 21:451
Rating of medication influences (ROMI) scale in schizophrenia, 20:297
Reevaluation of the mesolimbic hypothesis of antipsychotic drug action, 21:67
Schizophrenic deficits: Neuroleptics and the prefrontal cortex, 20:413
Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417
Weight gain associated with neuroleptic medication: A review, 21:463

Neurological soft signs

Neuropsychological correlates of violence in schizophrenia, 21:253

Neuromotor dysfunction

Cognitive/neuropsychological studies of children with a schizophrenic disorder, 20:647
Developmentally moderated expressions of the neuropathology underlying schizophrenia, 20:453
Neuromotor precursors of schizophrenia, 20:441

Neuropathology

Developmentally moderated expressions of the neuropathology underlying schizophrenia, 20:453
Structural brain abnormalities as indicators of vulnerability to schizophrenia, 20:89

Neuropsychology

Cognitive/neuropsychological studies of children with a schizophrenic disorder, 20:647
Flat affect in schizophrenia: A test of neuropsychological models, 20:311
Lack of insight in schizophrenia, 20:359
The need to integrate neuropsychological and experimental schizophrenia research, 20:1
Neuropsychological assessment of attention and its pathology in the Israeli cohort, 21:193
Neuropsychological correlates of violence in schizophrenia, 21:253
Neuropsychological risk indicators for schizophrenia: A review of family studies, 20:103
Response to Serper and Harvey, 20:13

Nigrostriatal system

Reevaluation of the mesolimbic hypothesis of antipsychotic drug action, 21:67

Norepinephrine

Assessment of the central dopaminergic index of plasma HVA in schizophrenia, 21:53

Nutrition

Time trends in schizophrenia: Changes in obstetric risk factors with industrialization, 21:483

O

Obstetric complications

Time trends in schizophrenia: Changes in obstetric risk factors with industrialization, 21:483

Onset of psychosis. *See* First-episode psychosis

Orofacial dyskinesia

Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia?, 20:339

Outcome. *See* Course and outcome

P

Pain insensitivity

Pain insensitivity in schizophrenia: A neglected phenomenon and some implications, 20:235

PANSS. *See* Positive and Negative Syndrome Scale

Paranoid personality disorder

Personality disorders among the relatives of schizophrenia patients, 20:481

Paraphrenia

Commentary to "Late-onset schizophrenia and late paraphrenia," 21:355
Late-onset schizophrenia and late paraphrenia, 21:345

Pathophysiology

Measuring liability to schizophrenia: Progress report 1994: Editors' introduction, 20:25

Patient assessment of treatment

Patients' assessment of treatment predicting outcome, 21:87

Patient rights

Individual psychotherapy and persons with serious mental illness: The clients' perspective, 21:283

Perceptual aberrations

Perceptual aberrations, schizotypy, and the Wisconsin Card Sorting Test, 20:345
Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: An update, 20:121

Personal therapy

Personal therapy: A disorder-relevant psychotherapy for schizophrenia, 21:379

Personality disorders

A family study of schizotypal disorder, 21:33
Personality disorders among the relatives of schizophrenia patients, 20:481

Pets

Could schizophrenia be a viral zoonosis transmitted from house cats?, 21:167
Evaluation of Torrey and Yolken's feline viral zoonosis theory of schizophrenia, 21:173

Pharmacotherapy. *See also specific drugs and classes of drugs by name*

Adjunctive treatments in schizophrenia: Pharmacotherapies and electroconvulsive therapy, 21:607
Antipsychotic maintenance treatment of schizophrenia patients: Is there a consensus?, 20:215
Can estradiol modulate schizophrenic symptomatology?, 20:203
Childhood-onset schizophrenia: An NIMH study in progress, 20:697
Childhood-onset schizophrenia: History of the concept and recent studies, 20:727
Children with schizophrenia: Diagnosis, phenomenology, and pharmacotherapy, 20:713
Clinical implications of clozapine discontinuation: Report of an NIMH workshop, 21:333
Clozapine: Efficacy and safety, 21:579
Conventional antipsychotic medications for schizophrenia, 21:567
Reevaluation of the mesolimbic hypothesis of antipsychotic drug action, 21:67
Risperidone: Efficacy and safety, 21:593

Phenomenology

Children with schizophrenia: Diagnosis, phenomenology, and pharmacotherapy, 20:713
The clinical presentation of childhood-onset schizophrenia, 20:631
Schizophrenia among Hispanics: Epidemiology, phenomenology, course, and outcome, 21:303

Photic driving

Abnormal photic driving responses in never-medicated schizophrenia patients, 21:111
Clozapine increases EEG photic driving in clinical responders, 21:263

Physical anomalies

Minor physical anomalies in schizophrenia patients, bipolar patients, and their siblings, 20:433

Polydipsia

Multidisciplinary approach to psychosis, intermittent hyponatremia, and polydipsia, 20:375

Positive and Negative Symptom Scale

Psychopathological dimensions in schizophrenia, 21:473

Positive symptoms

Childhood-onset schizophrenia: History of the concept and recent studies, 20:727
Vulnerability to delusions over time in schizophrenia and affective disorders, 21:95

Precursors

Developmentally moderated expressions of the neuropathology underlying schizophrenia, 20:453
Neuromotor precursors of schizophrenia, 20:441
Prodromal symptoms and relapse prevention in schizophrenia, 21:541
Prodromal symptoms of relapse in schizophrenia: A review, 21:527
Prodromal symptoms vs. early warning signs and clinical action in schizophrenia, 21:553
Schizophrenia: Treatment outcomes research—Editors' introduction, 21:561

Prefrontal cortex

Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

Prenatal infections. *See also* Viral infections

Gender differences in schizophrenia; Hormonal effect or subtypes?, 21:1
Geographic correlation of schizophrenia to ticks and tick-borne encephalitis, 20:755
Prenatal influenza infections and adult schizophrenia, 20:263
Twins with schizophrenia: Genes or germs?, 21:13

Prenatal risk factors

Prenatal development of monozygotic twins and concordance for schizophrenia, 21:357
Prenatal origin of schizophrenia in a subgroup of discordant monozygotic twins, 20:423
Time trends in schizophrenia: Changes in obstetric risk factors with industrialization, 21:483

Problem solving

Interpersonal problem solving and information processing in schizophrenia, 21:395

Prodromal symptoms

Prodromal symptoms and relapse prevention in schizophrenia, 21:541
Prodromal symptoms of relapse in schizophrenia: A review, 21:527
Prodromal symptoms vs. early warning signs and clinical action in schizophrenia, 21:553

Prognosis

Childhood-onset schizophrenia: History of the concept and recent studies, 20:727

Psychobiology

Event-related potentials as indicators of risk for schizophrenia, 20:63

Psychoeducational family management

Deliverability of psychoeducational family management, 20:547

Psychological tests

The multidimensionality of schizotypy, 21:19

Psychopathology. *See also* Experimental psychopathology

Psychopathological dimensions in schizophrenia, 21:473

Psychopharmacology. *See* Pharmacotherapy

Psychophysiology

Reanalysis of SCOR and anxiety measures in the Israeli High-Risk Study, 21:205

Psychosis proneness. *See also* Risk for schizophrenia

Prodromal symptoms and relapse prevention in schizophrenia, 21:541

Prodromal symptoms of relapse in schizophrenia: A review, 21:527

Prodromal symptoms vs. early warning signs and clinical action in schizophrenia, 21:553

Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: An update, 20:121

Single indicator of risk for schizophrenia: Probable fact or likely myth?, 20:151

Vulnerability to delusions over time in schizophrenia and affective disorders, 21:95

Psychosocial functioning

Psychological interventions for schizophrenia, 21:621

Psychosocial functioning and subjective experience in schizophrenia: A reanalysis, 21:405

Psychotherapy

Individual psychotherapy and persons with serious mental illness: The clients' perspective, 21:283

Personal therapy: A disorder-relevant psychotherapy for schizophrenia, 21:379

Psychological interventions for schizophrenia, 21:621

R

Racial differences

Trends in the inpatient care of persons with schizophrenia, 21:75

Recidivism

Cost of relapse in schizophrenia, 21:419

Relapse

Cost of relapse in schizophrenia, 21:419

Maintenance medication for schizophrenia and schizoaffective patients, 21:693

Prodromal symptoms and relapse prevention in schizophrenia, 21:541

Prodromal symptoms of relapse in schizophrenia: A review, 21:527

Repeated measures

Stability of diagnosis: Application to phenotype definition, 20:185

Risk for schizophrenia

Event-related potentials as indicators of risk for schizophrenia, 20:63

Family risk indicators in schizophrenia, 20:137

Impaired attention, genetics, and the pathophysiology of schizophrenia, 20:31

Indicators of liability to schizophrenia: Perspectives from genetic epidemiology, 20:169

Linkage study of a susceptibility locus for schizophrenia in the pseudoautosomal region, 20:277

Locus of control and mental health in adolescence and adulthood, 21:219

Measuring liability to schizophrenia: Progress report 1994: Editors' introduction, 20:25

Neuropsychological assessment of attention and its pathology in the Israeli cohort, 21:193

Neuropsychological risk indicators for schizophrenia: A review of family studies, 20:103

Overview and summary: Twenty-five-year followup of high-risk children, 21:227

Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: An update, 20:121

Reanalysis of SCOR and anxiety measures in the Israeli High-Risk Study, 21:205

Single indicator of risk for schizophrenia: Probable fact or likely myth?, 20:151

Structural brain abnormalities as indicators of vulnerability to schizophrenia, 20:89

Risperidone

Risperidone: Efficacy and safety, 21:593

S

Scales

Lack of insight in schizophrenia, 20:359

Perceptual aberrations, schizotypy, and the Wisconsin Card Sorting Test, 20:345

Rating of medication influences (ROMI) scale in schizophrenia, 20:297

Schizoaffective disorder

Maintenance medication for schizophrenia and schizoaffective patients, 21:693

Schizoid personality disorder

Personality disorders among the relatives of schizophrenia patients, 20:481

Schizophrenia spectrum

A family study of schizotypal disorder, 21:33

Schizotypal personality disorder

Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality, 20:191
Communication deficits in childhood schizophrenia spectrum disorders, 20:671
A family study of schizotypal disorder, 21:33
The multidimensionality of schizotypy, 21:19
Personality disorders among the relatives of schizophrenia patients, 20:481
Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: An update, 20:121
Schizotypal personality disorder in parents and the risk for schizophrenia in siblings, 21:47

Schizotypal Personality Questionnaire

Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality, 20:191

Schizotypy

Perceptual aberrations, schizotypy, and the Wisconsin Card Sorting Test, 20:345
Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: An update, 20:121

Skin conductance orienting response (SCOR)

Reanalysis of SCOR and anxiety measures in the Israeli High-Risk Study, 21:205

Seasonality of birth

Excess seasonality of births among patients with schizophrenia and seasonal ovopathy, 20:269
Seasonality of birth in schizophrenia in Taiwan, 21:117

Segregation analysis

Indicators of liability to schizophrenia: Perspectives from genetic epidemiology, 20:169

Selenium

Role of selenium and other trace elements in the geography of schizophrenia, 20:387

Serotonin

Are there neurochemical indicators of risk for schizophrenia?, 20:75

Sex chromosome anomalies

Linkage study of a susceptibility locus for schizophrenia in the pseudoautosomal region, 20:277
Schizophrenia and sex chromosome anomalies, 20:495

Siblings. *See also* Twin studies

Linkage study of a susceptibility locus for schizophrenia in the pseudoautosomal region, 20:277

Signal-to-noise ratio

Schizophrenic deficits: Neuroleptics and the prefrontal cortex—A reply, 20:417

Social deficits. *See* Affective deficits and social deficits

Social functioning

Information processing and social competence in chronic schizophrenia, 21:269
Interpersonal problem solving and information processing in schizophrenia, 21:395
Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia?, 20:339
Service providers in the social networks of clients with severe mental illness, 20:399

Socioeconomic factors

Time trends in schizophrenia: Changes in obstetric risk factors with industrialization, 21:483

Span of apprehension task

Information-processing deficits across childhood- and adult-onset schizophrenia, 20:685

Spectrum disorders

Childhood-onset schizophrenia: An NIMH study in progress, 20:697
Communication deficits in childhood schizophrenia spectrum disorders, 20:671
Delusions in schizophrenia spectrum disorders: Diagnostic issues, 20:747
Personality disorders among the relatives of schizophrenia patients, 20:481

Speech disorders

Speech and language disorders in children and adolescents with schizophrenia, 21:677

Statistical issues

Classifying the courses of schizophrenia, 20:519

Stigma

Dispelling the stigma of schizophrenia: What sort of information is best?, 20:567

First-person account: Self-stigmatization, 20:407
Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia?, 20:339

Structural brain abnormalities

Structural brain abnormalities as indicators of vulnerability to schizophrenia, 20:89

Structural Equation Modeling

Psychosocial functioning and subjective experience in schizophrenia: A reanalysis, 21:405

Subjective experiences

First person account: Adrift in an anchorless reality, 21:501
First person account: The evolution of a person with schizophrenia, 20:579
First person account: Insight from a schizophrenia patient with depression, 21:703
First person account: Life with a mentally ill spouse, 20:227
First person account: Living in a nightmare, 21:155
First person account: A personal experience, 21:339
First person account: Schizophrenia with childhood onset, 20:587
First person account: Self-stigmatization, 20:407
Psychosocial functioning and subjective experience in schizophrenia: A reanalysis, 21:405

Substance abuse comorbity

Assessment of alcohol and other drug disorders in the seriously mentally ill, 21:313
Expectations and motives for substance use in schizophrenia, 21:367

Survival analysis

Cost of relapse in schizophrenia, 21:419

Symptoms

Lack of insight in schizophrenia, 20:359
Prodromal symptoms and relapse prevention in schizophrenia, 21:541
Prodromal symptoms of relapse in schizophrenia: A review, 21:527
Prodromal symptoms vs. early warning signs and clinical action in schizophrenia, 21:553

T

Taiwan

Seasonality of birth in schizophrenia in Taiwan, 21:117

Tardive dyskinesia

Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia?, 20:339

Targeted medication

Deliverability of psychoeducational family management, 20:547

Taxometric procedures

Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: An update, 20:121

Therapy. *See* Personal therapy; Pharmacotherapy

Tick-borne diseases

Geographic correlation of schizophrenia to ticks and tick-borne encephalitis, 20:755

Treatment. *See also* Pharmacotherapy; *specific treatment by name*

Antipsychotic maintenance treatment of schizophrenia patients: Is there a consensus?, 20:215
Can estradiol modulate schizophrenic symptomatology?, 20:203
Childhood-onset schizophrenia: An NIMH study in progress, 20:697
Childhood-onset schizophrenia: History of the concept and recent studies, 20:727
Children with schizophrenia: Diagnosis, phenomenology, and pharmacotherapy, 20:713
Clinical implications of clozapine discontinuation: Report of an NIMH workshop, 21:333
Deliverability of psychoeducational family management, 20:547
Individual psychotherapy and persons with serious mental illness: The clients' perspective, 21:283
Schizophrenia: Treatment outcomes research—Editors' introduction, 21:561
Treatment outcomes in schizophrenia: Implications for practice, policy, and research, 21:669

Twin studies. *See also* Family studies

Prenatal development of monozygotic twins and concordance for schizophrenia, 21:357
Twins with schizophrenia: Genes or germs?, 21:13

U

Urinalysis

Assessment of the central dopaminergic index of plasma HVA in schizophrenia, 21:53

V

Vermis

Cerebellum and schizophrenia: A selective review, 21:241

Violence

Neuropsychological correlates of violence in schizophrenia, 21:253

Viral infections

Could schizophrenia be a viral zoonosis transmitted from house cats?, 21:167
Evaluation of Torrey and Yolken's feline viral zoonosis theory of schizophrenia, 21:173
Gender differences in schizophrenia: Hormonal effect or subtypes?, 21:1
Geographic correlation of schizophrenia to ticks and tick-borne encephalitis, 20:755
Pain insensitivity in schizophrenia: A neglected phenomenon and some implications, 20:235

Vocational rehabilitation

Vocational rehabilitation in schizophrenia, 21:645

Vulnerability factors

Information-processing deficits across childhood- and adult-onset schizophrenia, 20:685
Medical conditions in Ashkenazi schizophrenic pedigrees, 20:507
Psychometric high-risk paradigm, perceptual aberrations, and schizotypy: An update, 20:121
Single indicator of risk for schizophrenia: Probable fact or likely myth?, 20:151

W

Weight gain

Weight gain associated with neuroleptic medication: A review, 21:463

Wisconsin Card Sorting Test

Perceptual aberrations, schizotypy, and the Wisconsin Card Sorting Test, 20:345

XXX and XXY chromosomes

Schizophrenia and sex chromosome anomalies, 20:495